Safety issues contribute to ~25% of the attrition in drug projects. When safety issues occur as a result of secondary pharmacology, there is an option to choose a more selective compound or adjust the chemistry to avoid it.

Currently, to address secondary pharmacology, most biopharmaceutical companies screen their small molecule compounds off in a broad panel of off-target receptors, which can be labor- and time-intensive, taking weeks.

The key challenge is in interpreting the readout in the context of the predicted plasma concentrations: which of the ‘hits’ are going to contribute adverse effects in clinical development and post-marketing? Get it wrong and there is a price to pay further down the line, when everything is far more expensive.

Our new Secondary Intelligence™ Software is the only tool available to address this translational challenge.

  • Predict off-target adverse events, earlier, faster and cheaper
  • Streamline and standardize your secondary pharmacology analysis
  • Increase confidence in go/no go decisions

Researchers can either license our software and use it directly to conduct turnkey secondary pharmacology analysis, or you can rely on our team of scientists to run the analysis for you and provide you with the support that you need to advance your program.

Easily understand the likelihood of off-target interaction

Secondary Intelligence software identifies the key safety information about each receptor, allowing you to focus on how a test compound interacts with that receptor.

Secondary Intelligence ranks the likelihood of each off-target interaction during clinical use, color-coding in red, amber or green, based on quantitative analysis of clinically used drugs that specifically target that receptor, and on its predicted plasma Cmax.

Make more confident decisions on which compounds to move forward

Secondary Intelligence prioritises “receptor interactions of concern” in a variety of data representations and ranks compounds against each other to make quantitatively based decisions as to which compounds to progress.

Secondary Intelligence will integrate with Certara’s Simcyp® PBPK software platform, the leading physiologically-based pharmacokinetic simulator. This integration is crucial for the assessment of the relevant tissue concentrations.

A more efficient and accurate method to predict adverse events

The use of personal opinion and judgement to interpret screening panel readouts is inefficient and prone to error. We have rigorously built Secondary Intelligence with robust methodology, research, and analysis.

• Secondary Intelligence assembles curated, organised information for a compound’s secondary pharmacology readouts and analysis in one place
• It provides up-to-date literature-based information on the expected side effects of a given compound if it engages with a particular off-target receptor in clinical use.
• This data enables virtual in vitro in vivo extrapolation (IVIVE)

Contact us to learn more
Will Redfern, PhD Vice President, Quantitative Systems Toxicology and Safety

QSTS チームを統率し、計算科学アプローチを駆使した医薬品やその他の化学物質の安全性評価に取り組んでいます。豊富な実績を誇る安全性薬理学者として、過去に Syntex、Quintiles、AstraZeneca において研究に従事していました。2017 年には Safety Pharmacology Society の President を務めていました。

Mark Holbrook, PhD Senior Scientific Advisor, Quantitative Systems Toxicology and Safety

Celltech、AstraZeneca、Pfizer および Covance において 30 年以上にわたって創薬および開発の経験を積んできました。現在は、サターラの QSTS チームに安全性薬理学および毒性学に関する専門的な助言を提供しています。

How Can We Help?

Powered by GlobalLink OneLink Software